Sage Journals: Discover world-class research

Abstract

Because of the current COVID-19-pandemic, the world is currently being held hostage in various lockdowns. ACE2 facilitates SARS-CoV-2 cell-entry, and is at the very center of several pathophysiological pathways regarding the RAAS, CS, KKS, T2DM, and IL-6. Their interactions with severe COVID-19 complications (e.g. ARDS and thrombosis), and potential therapeutic targets for pharmacological intervention, will be reviewed.

Keywords

COVID-19 angiotensin-converting enzyme 2 renin angiotensin aldosterone system complement kallikrein-kinin system thrombosis interleukin-6 diabetes

Introduction

The aim of this review is to create a framework of different interconnected pathways that constitute the complex COVID-19 pathophysiological crossroads, as well as the interactions with common comorbidities (T2DM in particular).

First the SARS-CoV-2 virus and COVID-19 (including severe complications) will be introduced. Then, the COVID-19 relation with the RAAS will be reviewed, and a preliminary framework will be established. This framework will subsequently be expanded with the CS and the KKS. The interactions between COVID-19, T2DM, and IL-6, will be reviewed in light of this framework. Finally, some potential targets for therapeutic intervention will be discussed.

Abbreviations are listed at the end.

COVID-19

SARS-CoV-2 is a SSRNA⁺, enveloped virus from the beta-coronavirus family, with a structural surface spike (S) glycoprotein that primarily binds to the N-terminal domain of ACE2, predominantly, but not exclusively, on type-II pneumocytes.^1–3 SARS-CoV-2 decreases surface ACE2 expression through directly binding to ACE2,^4–6 followed by TMPRSS2-mediated proteolytic cleavage^3,7,8 and subsequent endocytosis.^1,3,5 TMPRSS2 is essential for SARS-CoV-2 membrane fusion and subsequent cell-entry,^3,7,8 but other proteases (such as Furin) may facilitate SARS-CoV-2 cell-entry as well.^2,5,9 Surface ACE2 is further reduced via shedding, caused by Ang-II-mediated upregulation of ADAM-17^5,6,10 and androgen-mediated^8,11 upregulation of TMPRSS2.^3,7 Reduced ACE2 expression may also be modulated epigenetically via DNA-methylation processes,^12,13 or via crosstalk with T2DM-induced hyperglycemia.^14,15

The SARS-CoV-2-related disease is commonly referred to as COVID-19.^1,7,16 Common COVID-19 symptoms are fever, dry cough, sore throat, dyspnea, headache, and myalgia.^1,12,17 Some atypical symptoms are anosmia (loss of smell)^18–20 and diarrhea (which may present earlier than respiratory conditions).^1,5,17 Different sex and age groups have very biased severity and mortality of COVID-19, with male, old age, and comorbidity being the most affected.^1,4,15 T2DM, hypertension, and CVD are common COVID-19 comorbidities (which are likely related to a dysregulated RAAS)^5,6,21 and are associated with ARDS^15,22,23 and high fatality.^1,23,24 Currently, there is no approved and effective medication against COVID-19.^16,22,25

The protective mechanism during the early stages of a (viral) infection predominantly occurs through the innate immune system.^26–28 COVID-19 primarily suppresses the innate immune system, enabling the uncontrolled spread of the virus during the initial stages.^27–29 This explains a mild (sometimes even asymptomatic) presentation early on.^27,28,30 The high effectiveness of the innate immune system in children possibly explains why COVID-19 doesn’t seem to affect them as much (if at all).^27,28,30 Differences in immunity^27,28,31 and gene expression^4,12,22 may contribute to COVID-19 severity. Severe COVID-19 complications are associated with excessive and dysregulated host immune responses, which may contribute to the development of lethal CRS and ARDS.^32–34

Acute respiratory distress syndrome

ARDS, the most severe form of ALI,^35–37 is a clinical syndrome of noncardiogenic pulmonary edema.^38–40 ARDS is characterized by an excessive inflammatory response,^41–43 damage to both alveolar epithelial^38,40,41 and vascular endothelial^39,44,45 cells, the subsequent breakdown of the alveolar-capillary barrier integrity,^38,42,46 impaired AFC,^40,41,45 excessive interstitial and parenchymal neutrophil migration,^38,43,45 and activation of alveolar macrophages, platelets, and pro-coagulant processes.^42,47,48 This may result in diffuse alveolar damage,^42,49 pulmonary fibrosis,^37,50 and impaired gas exchange,^42,51 leading to (refractory) hypoxemia^35,38,42 and possibly organ dysfunction.^40,47,52

Uncontrolled inflammation leads to excessive and prolonged activation of neutrophils,^38,43,45 which are immune cells that play an important role in the regulation of IL-6 signaling^53–55 in the pathology of pulmonary inflammatory disorders.^38,43,56 Neutrophil-mediated ROS production (via NADPH oxidase),^57,58 plays an essential part in the immune response against pathogens via NET formation and direct cellular damage.^59–61 Excessive neutrophil recruitment therefore contributes significantly to the severity of inflammatory pneumonia.^56,60,62

In AFC, alveolar fluid is cleared via an ENaC-mediated osmotic gradient.^40,41,63 Disruption of ENaCs can lead to impaired AFC.^42,62,64

The ECM is important for the epithelial and endothelial barrier function, since it regulates intercellular interactions and controls the migration of fluid and molecules in the interstitial space.^42,65 Changes in ECM composition affect the mechanical properties of tight-junctions in alveolar epithelial and vascular endothelial cells, modulating the alveolar-capillary barrier function.^42,66 Excess deposition of ECM proteins can lead to pulmonary fibrosis,^37,42,50 which may lead to chronic impairment of pulmonary function in ARDS survivors.⁵⁰ The amount of alveolar epithelial damage and impaired AFC capability are associated with impaired gas exchange and higher mortality.^41,42,62 Injury of the alveolar epithelium (not the vascular endothelium) determines the progression to pulmonary fibrosis.^42,67,68 Currently there is no specific treatment for post-ARDS pulmonary fibrosis other than supportive therapy.^50,69

ARDS is one of the leading causes of death in ICU patients.^38,40,41 Current ARDS therapy mainly constitutes supportive treatments, such as mechanical ventilation.^51,70,71 This is predominantly effective in less severe cases, and may have serious side-effects.^38,70,71 High tidal volume mechanical ventilation upregulates ACE expression and Ang-II activity,⁷¹ activates JNK and ERK_1/2,⁷² and increases pulmonary parenchymal IL-6 levels via excessive alveolar distention.⁷⁰ Mechanical ventilation may promote ventilator-induced ALI, which is characterized by inflammation, increased vascular permeability, interstitial pulmonary edema, parenchymal infiltration, fibrosis, and thrombosis.^42,48,71

The COVID-19-related ARDS may present atypically, in the sense that there is relatively well-preserved pulmonary compliance (despite the severity of hypoxemia), and systemic features of a hypercoagulable state.^73–75 To understand how and why, a trinity of interconnected systems will be discussed, starting with the RAAS.

Renin angiotensin aldosterone system

To explain why changes in ACE2 and Ang-II levels are important in COVID-19, we need to discuss their interactions with other relevant systems, as well as their relation to comorbidities and complications.

If we exclusively focus on the RAAS, it is best described as a regulatory system with two axes that control vasoconstriction and vasodilation,^3,76,77 which play an essential role in maintaining hemodynamic homeostasis.^64,78,79 The classical ACE/Ang-II/AT1R axis promotes vasoconstriction.^37,80,81 Renin increases Ang-I, which is subsequently converted to Ang-II by ACE,^35,77,82 after which Ang-II exerts its cellular effects (predominantly via the AT1R).^58,79,83 The counterregulatory ACE2/Ang-(1-7)/MasR axis promotes vasodilation.^3,76,77 ACE2 converts Ang-II to Ang-(1-7), which exerts its cellular effects predominantly via the MasR.^64,79,80

In a perfectly balanced RAAS, neither ACE nor ACE2 should be considered good or bad, as they are both required to maintain healthy homeostasis. Since ACE is required for either axis, Ang-II and ACE2 should be considered to be the main effectors of the RAAS. This balance can go either way, meaning low ACE2/high Ang-II or high ACE2/low Ang-II. Since only low ACE2/high Ang-II is relevant regarding COVID-19, the focus will be on that type of RAAS imbalance in particular.

Ang-II will be considered first, after which ACE2 will be discussed.

Angiotensin-II

Ang-II is considered to be the major player in the ACE/Ang-II/AT1R axis.^41,83,84 A dysregulated RAAS (and associated elevated Ang-II levels) has many detrimental effects. Ang-II upregulates Aldosterone production and promotes hypertension,^83–85 CVD,^78,79,82 and fibrosis.^71,80,86 Furthermore, elevated Ang-II levels increase PKC-mediated^87–89 ROS production via NADPH oxidase^86,90,91 and ΔΨ_M depolarization (through PKC-mediated modulation of K_ATP channels).^58,91,92 Ang-II-mediated ROS production stimulates ERK_1/2,^58,88,93 JNK,^91,94,95 and p38-MAPK,^83,90,96 subsequently initiating crosstalk with NF-κB^64,71,89 (Figure 1).

Figure 1.

ROS- and IL-6-mediated MAPK signaling and their effects regarding severe COVID-19 complications, for example, ARDS and thrombosis.

ERK_1/2, JNK and p38-MAPK are members of the MAPK family, and are preferentially activated by inflammation and environmental stresses (JNK and p38-MAPK in particular).^97–99 MAPK signaling plays a crucial role in regulating cell apoptosis, inflammatory responses, and cell-cell junction formation.^14,72,96 NF-κB is a transcription factor family that plays an important immunoregulatory role,^44,100,101 and modulates the production of inflammatory cytokines^44,86,89 and NADPH oxidase subunits.^102–104

Ang-II-induced ROS production effectively induces insulin resistance,^79,86,94 and exacerbates T2DM.^64,86,89 Insulin resistance impairs the PI3K/Akt/eNOS pathway,^94,105,106 subsequently reducing glucose uptake and NO production.^86,88,89 Insulin signaling, and the role of Ang-II in insulin resistance, will be further discussed in the T2DM section. To understand the importance of Ang-II-mediated reduction of NO bioavailability in COVID-19, we will first consider the vascular endothelium.

Vascular permeability

The inner surface of the vascular tree is lined with a continuous monolayer of endothelial cells (joined together by tight-junctions), forming a protective selective permeability barrier between the circulating blood and the extravascular tissue.^39,107,108 The endothelium is a metabolically active homeostatic organ, regulating the tone, structure and permeability of the vascular system in response to different stimuli (e.g. shear stress, ACh, and insulin).^46,78,104 Limited vascular permeability is a function of a balanced endothelial phenotype, which constitutes smooth muscle relaxation, as well as low platelet activation and low fibrin formation.^78,109,110 Endothelial dysfunction disrupts this balance and predisposes the vascular wall to inflammation, platelet activation, dysregulated coagulation, thrombosis, and increased vascular permeability.^39,48,111

Both the disruption of endothelial tight-junctions^39,72,108 and impaired NO bioavailability^104,109,112 are two important causes of endothelial dysfunction and increased vascular permeability. ROS-mediated MAPK signaling is responsible for disruption of endothelial tight-junctions.^39,72,108 Impaired NO bioavailability occurs via eNOS uncoupling,^104,109,113 reduced eNOS activity,^74,112,114 or ROS-scavenging.^55,104,115 Prolonged and excessive vascular permeability can result in tissue damage, organ dysfunction, or even death.^116,117

Impaired NO bioavailability plays a role in thrombosis, due to the hampering effect of NO on ROS-mediated upregulation of platelet activation, suggesting that either decreased NO bioavailability or increased ROS production is able to induce thrombosis.^114,118 Endothelial dysfunction initiates the coagulation pathway by activating platelets and pro-coagulant cascades, while reducing anti-coagulant components and fibrinolysis.^42,114 This results in pulmonary capillary microthrombi and fibrin deposition in parenchymal and interstitial compartments,⁴² which is characterized by observed high D-dimer and von Willebrand Factor in some COVID-19 patients.^21,119,120

During an inflammatory state, endothelial cells release von Willebrand Factor,^110,120 which represents an important thrombotic risk factor.^48,121 Von Willebrand Factor is a large adhesive glycoprotein, synthesized by endothelial cells,^46,110,120 and is critical for platelet adhesion and aggregation.^48,121 ABO blood group genes affect von Willebrand Factor expression, as well as their susceptibility to proteolytic degradation via ADAMTS13.¹²² This is a possible explanation why ABO blood group type may be differentially related to COVID-19 severity.¹²²

Ang-II-mediated ROS production^58,90,91 and decreased NO bioavailability^79,94,123 promote vascular permeability^41,81,83 and thrombosis^6,80,82 (Figure 1). Ang-II-mediated disruption of ENaCs impairs AFC,^41,64,124 exacerbating pulmonary edema.^40,62,63 These are essential components of ARDS,^41,42,62 which is a severe COVID-19 complication.^25,76,125 Ang-II is significantly elevated in COVID-19 patients and is highly associated with viral load and lung injury.^21,76,125

Angiotensin-converting enzyme 2

The ACE2/Ang-(1-7)/MasR axis can mitigate Ang-II-mediated negative effects.^77,79,81

ACE2 is a homologue of ACE,^78,82,84 and a key component of the RAAS.^77,81,126 ACE2 is a two-part type-I transmembrane protein, consisting of a glycosylated extracellular N-terminal domain (containing the SARS-CoV-2-binding carboxypeptidase site), and an intracellular C-terminal cytoplasmic tail.^3,127,128 The extracellular catalytic domain of ACE2 can be cleaved and released by ADAM-17^5,6,76 or TMPRSS2.^2,3,8 ACE2 is widely expressed in the heart, kidneys, lungs, CNS, and intestines,^80,82,84 and is present in type-II pneumocytes and endothelial cells.^6,71,129 ACE2 is predominantly membrane-bound, although it does exist, with a short half-life,^52,130 in soluble form.^3,6,127

Increased ACE2 expression, upregulating the ACE2/Ang-(1-7)/MasR axis, has multiple beneficial effects, for example, mitigation of hypertension,^80,84,131 CVD,^77,82,129 insulin resistance,^79,132,133 and T2DM.^5,25,134 ACE2 also increases NO bioavailability,^79,80,135 subsequently mitigating endothelial dysfunction,^76,82,133 vascular permeability^43,64,76 and thrombosis.^6,76,136 Furthermore, via decreased MAPK signaling,^44,71,137 ACE2 reduces inflammation,^3,43,71 ROS production,^78,138,139 and neutrophil accumulation.^56,76,95 In this manner, ACE2 protects against pulmonary edema,^35,75,76 fibrosis,^64,71,77 and ARDS.^38,43,81

Low ACE2 expression has been associated with hypertension, CVD, T2DM, inflammation, and ARDS,^4–6 which happen to be risk factors for (severe) COVID-19 complications.^1,15,23 Since ACE2 is the SARS-CoV-2 cell-entry point,^2,3,6 there has been speculation that elevated ACE2 expression may increase susceptibility for SARS-CoV-2 infection.^140–142 ACE2 expression is higher in females than in males,^4,134 and declines with age^5,141 (in men more so than in women).^6,143 This can be explained by the upregulation of ACE2 expression by Estrogen,^4,131 and the X-chromosomal location of the ACE2 gene^3,129,144 (which is regulated epigenetically via DNA methylation).^12,13 DNA methylation is associated with biological age,^12,145,146 which suggests that biological age may be a more accurate risk factor for severe COVID-19 complications compared to chronological age.^13,147 This pattern of ACE2 expression may partly explain why elevated ACE2 levels possibly have no negative effects on COVID-19 susceptibility.^4,6,134 Also, there is a negative correlation between ACE2 expression and COVID-19 fatality.^4,5,144 SARS-CoV-2-induced downregulation of ACE2 expression may especially be detrimental in people with comorbidities, since they initially have a lower ACE2 baseline.^4,6,21 Additional COVID-19-mediated ACE2 deficiency may amplify the RAAS dysregulation,^5,6,76 resulting in upregulation of Ang-II, which is indeed significantly elevated in COVID-19 patients.^21,76,125 In the lungs, such dysregulation can induce the progression of inflammatory and thrombotic processes, because Ang-II is now unopposed by ACE2.^6,21,125 This suggests that ACE2 may not be the culprit in COVID-19, but may actually have an important protective role, despite the ACE2-mediated cell-entry mechanism of SARS-CoV-2.^5,76,134 A low ACE2 expression (or reserve) may contribute to the progression of COVID-19 to a (more) severe or fatal stage.^4,6,125 Because of the high intrinsic affinity of ACE2 with the SARS-CoV-2 spike (S1) proteins,⁶ a lower ACE2 expression may not affect the susceptibility for SARS-CoV-2 infection at all.^6,127

Although many effects of ACE2 have been attributed to the downregulation of Ang-II levels, other substrates play a major role in ACE2-related functions as well.^56,64,81

The framework we have now established consists of the following hypothesis: “a SARS-CoV-2-induced RAAS imbalance, comprised of reduced ACE2 expression (and a subsequent elevated Ang-II activity), plays a role in severe COVID-19 complications.”

There are still many loose ends in this narrative. In order to connect these, two more systems will be discussed, that is, the CS and the KKS. The CS and the KKS are linked.^107,148,149 The KKS and the RAAS are linked as well.^25,56,64 The RAAS, CS, and KKS, form a trinity of systems with several regulatory axes contributing to severe COVID-19 complications.

Complement system

The CS is an important component of the innate immune system, involved in host defense against micro-organisms, clearance of immune complexes and removal of apoptotic cells,^149–151 and is intrinsically linked to the coagulation pathway.^21,151,152 The CS is a key mediator of lung damage during (corona virus) infections, raising the possibility that CS activation may play a role in severe COVID-19 complications.^16,74,153

Although most CS components are synthesized in the liver, type-II pneumocytes provide local CS proteins.^154–156 The CS components C1, C3_a, C5_a, as well as the C5_b-C9 MAC, all contribute to increased endothelial permeability.^107,157,158

The CS can be activated via three pathways, that is, the classical, lectin, or alternative pathway.^154,159,160 The classical pathway entails the creation of immune complexes with IgM/IgG antibodies, binding predominantly to pathogenic antigens.^107,159,161 C1 binds to the antibody and forms C3 and C5, via initiating a series of enzymatic cascades.^107,154,162 C3 and C5 are both cleaved to C3_a/C3_b and C5_a/C5_b respectively.^107,154,160 C3_a and C5_a act as chemotactic agents for phagocytes.^107,151,154 C3_b is involved in opsonization of pathogens that are subsequently destroyed by phagocytes.^107,154,159 C5_b-C9 forms a MAC that induces cell-lysis by punching holes through their membranes.^107,154,161 The lectin pathway involves the interaction of MBL with the pathogen (or the surface of a pathogen-infected cell), followed by the subsequent binding and activation of MASP2, directly activating similar CS cascades as in the classical pathway.^74,153,154 The alternative pathway involves a spontaneous conformation change of C3, and after a short cascade, C3 is cleaved into C3_a and C3_b without the use of antibodies, leading to similar cascades as the classical pathway.^151,154,163 The CS is inhibited by the SerPin C1_INH via inhibition of C1 in the classical pathway, MASP2 in the lectin pathway, and C3_b in the alternative pathway.^107,149,164

Excessive CS activation can lead to inflammation and (excessive) neutrophil recruitment via opsonization and (via C3_a- and C5_a-mediated)^107,153,156 chemotaxis.^16,148,153 Excessive CS activation (on the endothelial surface) can lead to vascular problems, for example, endothelial damage (via MAC-induced lysis),^74,148,154 vascular permeability,^107,148,158 thrombosis,^148,151,152 (diffuse) TMA,^159,162,165 and DIC.^161,166,167 This is how excessive CS activation exacerbates ARDS,^16,74,154 pulmonary fibrosis,^50,168,169 and possibly organ dysfunction.^16,151,159

In at least a subset of severe COVID-19 patients an excessive CS activation is found via the lectin pathway,^153,170,171 as demonstrated by elevated C5_b-C9 MAC components, MBL-MASP2 in the pulmonary microvasculature, and parenchymal neutrophils.⁷⁴ This is consistent with sustained and systemic CS activation and an associated pro-coagulant state.^21,74 A possible modus operandi for additional CS activation via the lectin pathway in COVID-19 is the binding of SARS-CoV-2 N-proteins to MASP2.¹⁵³ This leads to excessive CS activity,^153,171 further exacerbating CS-mediated MAC formation, inflammation, and concurrent activation of the coagulation pathway,^21,74 resulting in ARDS^16,153 and thrombosis^74,170 (Figure 2). The observed high D-dimer and von Willebrand Factor (and its associated thrombotic activity) in severe COVID-19 patients,^111,119,120 can at least be partially explained by excessive CS activation (and associated MAC-mediated endothelial dysfunction), followed by an activated coagulation pathway.^74,153,159

Figure 2.

The CS including the COVID-19-induced lectin pathway feedback mechanism.

Our framework can now be expanded with the hypothesis: “an excessive CS activation plays a significant role in severe COVID-19 complications.”

The CS is not only linked to the coagulation pathway,^151,161,166 but to the KKS as well,^107,148,149 which will be discussed next.

Kallikrein-kinin system

The KKS, like the CS, is an important part of the innate immune system,^149,172,173 and is activated during inflammation.^148,164,174 The KKS consists of Hageman Factor (Factor XII), PK, HK, the proteolytic KK enzymes, and effector peptides, such as BK (and its active metabolite des-Arg⁹-BK).^107,149,164 Factor XII gets activated via inflammatory processes and converts to Factor XII_a, which in turn converts PK into KK, initiating the kinin cascade^107,149,164 (cleaving HK to generate BK and other metabolites, such as des-Arg⁹-BK).^85,148,164 Factor XII_a also turns Factor XI into Factor XI_a, subsequently activating the coagulation pathway, linking it to the KKS.^107,149,175 KK turns Factor XII_a into Factor XII_f, which initiates the CS via C1_r cleavage, linking the KKS directly to the CS.^107,149,176 KK also turns pro-Renin into Renin, linking the KKS directly to the RAAS.^64,177,178 All these processes are inhibited by the SerPin C1_INH.^107,149,164

The kinin BK is not very stable, and is easily degraded by ACE.^81,85,88 Another kinin, des-Arg⁹-BK, is much more stable than BK,^148,164,179 but can be degraded by ACE2.^25,56,64 This shows another direct link between the KKS and the RAAS.^36,75,81

KKS signaling is mediated by two receptors, B2R and B1R.^85,148,180 While the B2R is ubiquitously expressed in most healthy tissues, B1R is synthesized de-novo and upregulated as a consequence of tissue injury or inflammatory processes.^81,164,180 BK is the primary ligand for B2R, whereas des-Arg⁹-BK is the primary ligand for B1R.^85,107,148

Kinins are potent inflammatory mediators,^36,88,164 increasing vascular permeability^85,180,181 and neutrophil recruitment.^56,148,174 This may lead to inflammation,^25,148,180 edema,^75,164,180 and pain.^85,164,174 Uncontrolled and excessive KKS activation, or abnormal kinin degradation, can cause an acute accumulation of BK and/or des-Arg⁹-BK, leading to excessive inflammation.^56,107,148 Excessive KKS activation may also promote T2DM via (MAPK-mediated)^181–183 destruction of pancreatic Langerhans islets,^85,184,185 and increase vascular permeability.^148,164,180 This results in exacerbated edema,^85,107,164 neutrophil migration,^56,148,174 thrombosis,^148,186,187 ARDS,^25,75,188 and possibly even organ dysfunction.^25,187,189

The KKS and the CS are intrinsically linked at multiple levels, and are both activated during (vascular) inflammation (i.e. via gC1_qR, which binds both C1_q and HK).^107,148,149 Simultaneous and uncontrolled excessive activation of both the KKS and CS (on the endothelial surface) is largely responsible for increased vascular permeability and edema.^107,148,149 KK, which cleaves HK and subsequently releases BK, also cleaves and activates C3.^148,190,191 The KKS^107,148,149 and CS^150–152 are both intrinsically linked to the coagulation pathway. The endothelial permeability-inducing effect of the C5_b-C9 MAC is regulated by BK.^107,192,193 The KKS and CS are both inhibited by C1_INH.^148,149,164

ACE2 degrades the otherwise stable des-Arg⁹-BK.^56,64,81 SARS-CoV-2 reduces ACE2 expression.^3,6,125 A reduction in pulmonary ACE2 subsequently increases Ang-II^5,125,194 and impairs the degradation of the des-Arg⁹-BK/B1R axis of the KKS.^6,25,56 This exacerbates neutrophil migration^56,148,174 and ARDS.^25,56,75 The des-Arg⁹-BK/B1R axis of the KKS is not affected by corticosteroids,^195–197 which means that as long as the virus is present, ACE2 will not be, and the kinin-induced ARDS will persist.⁷⁵

We now have established multiple connections between the RAAS, CS, KKS, and the coagulation pathway. In our trinity of systems, the RAAS^3,76,77 controls vasoconstriction and vasodilation, whereas the KKS^85,180,181 and the CS^107,158,198 control vascular permeability and vasodilation. ACE2 is the one ring that rules them all⁷⁵ (Figure 3). The SerPin C1_INH effectively suppresses the KKS,^107,149,164 the coagulation pathway,^107,151,152 and all three pathways of the CS.^150,152,176

Figure 3.

The trinity of systems: RAAS, CS, KKS, and their interconnections, as well as their interactions with IR, the coagulation pathway, inflammation, and COVID-19.

Our framework can now be further expanded with the hypothesis: “a SARS-CoV-2-induced reduction of ACE2 expression directly causes a disruption and excessive activation of the KKS, which is not only able to further activate an already active CS, but directly plays a significant role in the exacerbation of severe COVID-19 complications.”

Next, the T2DM interactions with our trinity of systems will be discussed.

Type-2 diabetes mellitus

T2DM is considered to be a metabolic disease, comprising insulin resistance and pancreatic β-cell dysfunction, resulting in insulin deficiency and subsequent hyperglycemia.^99,104,199 T2DM is characterized by comorbid conditions of CVD^89,104,200 and hypertension.^89,201,202 T2DM is also associated with vascular problems, for example, endothelial dysfunction, vascular permeability, platelet dysfunction, and hypercoagulation.^113,203,204 This can be partially contributed to a dysregulated RAAS^5,94,105 (low ACE2^4,5,82 and high Ang-II^79,94,106). CVD is the main complication of T2DM.^114,204,205 However, clinical CVD can also precede the development of T2DM,^200,206,207 suggesting that T2DM and CVD may both have an underlying cause, for example, a chronic low-grade inflammatory state,^199,208,209 insulin resistance,^53,210,211 or a dysregulated RAAS.^86,89,133

Obesity

In T2DM, macrophage infiltration into expanding adipose tissue and pancreatic islets,^212–214 as well as macrophage polarization toward the M1 phenotype^99,215,216 (as a result of IL-6 trans signaling),^53,214,217 is involved in the development of chronic low-grade inflammation in obese individuals.^199,208,218 Visceral adipose tissue in particular, is characterized by high secretion of inflammatory cytokines, and T2DM patients have more visceral adipose tissue than nondiabetics.^53,98,219 Furthermore, inflammatory cytokines in adipose tissue stimulate JNK and NF-κB,^99,214,220 which induces insulin resistance.^98,199,221 Finally, the RAAS may be disrupted in expanding visceral adipose tissue, exacerbating inflammation and insulin resistance.^6,222,223

Insulin resistance

P(Tyr)IRS-1 is required for insulin-stimulated activation of the PI3K/Akt/eNOS pathway^99,206,224 and multiple downstream effectors that promote glucose uptake and NO production.^112,225,226 NO has vasoprotective effects,^79,227,228 and its bioavailability depends on the balance between the rate of its eNOS-mediated production and its ROS-mediated inactivation.^104,109,229

Increased P(Ser)IRS-1 and decreased P(Tyr)IRS-1^98,224,230 (both induced by JNK and ERK_1/2) disrupt insulin signaling,^94,199,206 preventing activation of the PI3K/Akt/eNOS pathway.^99,115,231 Chronic P(Ser)IRS-1 also targets IRS-1 for degradation or migration to inaccessible subcellular compartments.^54,89,232

Hyperinsulinemia, caused by insulin resistance, activates both JNK^230,232,233 and ERK_1/2.^88,234,235 Subsequently this further stimulates P(Ser)IRS-1,^97,99,230 which is how hyperinsulinemia exacerbates insulin resistance.^94,232,236 Hyperinsulinemia also upregulates Ang-II, which is how insulin resistance may disrupt the RAAS.^89,237,238

Ang-II-mediated ROS production increases P(Ser)IRS-1^79,88,94 and decreases P(Tyr)IRS-1,^86,89,105 effectively inducing insulin resistance^87,239,240 (Figure 1). A vicious cycle between the RAAS and insulin resistance has now been created.^89,241,242

Insulin resistance is a risk factor for T2DM,^86,206,232 obesity,^85,98,106 hypertension,^88,89,105 and CVD.^87,210,243

β-Cell dysfunction

The progression from insulin resistance to T2DM implicates the inability of pancreatic β-cells to compensate for increased insulin demand.^53,221,244

Sustained JNK activation causes pancreatic β-cell dysfunction,^230,232 especially in obese individuals with an exacerbated inflammatory milieu.^99,199,221

IL-6 increases the proliferation of α-cells and apoptosis of β-cells in the pancreas,^53,245,246 suggesting a link between IL-6 and T2DM.^208,218,247 The role of IL-6 in the proliferation of α-cells may initially compensate for the impaired β-cells in T2DM and contributes to limit hyperglycemia.^53,245,248

Hyperglycemia increases IL-6 levels, both systemically and locally in pancreatic Langerhans islets,^53,249,250 and promotes β-cell death^99,246,251 (Figure 1).

In T2DM, the KKS is activated and kinins cause damage to pancreatic Langerhans islets, suggesting a link between the KKS and T2DM.⁸⁵

Furthermore, in T2DM, ACE2 expression is downregulated,^15,133 and increased Ang-II plays a part in reducing β-cell function via ROS-mediated apoptosis,^89,252 suggesting a link between RAAS disruption and T2DM.^64,86,89

Hyperglycemia

Pancreatic β-cell dysfunction leading to T2DM results in insulin deficiency and subsequent hyperglycemia,^104,115,221 which has a plethora of detrimental effects.

Hyperglycemia increases the production of IL-6^53,55,250 and AGEs.^104,113,253 AGEs bind to RAGEs^99,104,254 (which are expressed on the surface of many cell types, including endothelial, epithelial, and immune cells),^62,113,255 and subsequently increases PKC-mediated^55,256,257 ROS production via NADPH oxidase.^118,203,258 Hyperglycemia-mediated ROS production stimulates ERK_1/2,^259–261 JNK,^99,262,263 and p38-MAPK,^264–266 subsequently initiating crosstalk with NF-κB^86,104,267 (Figure 1). This ROS-mediated MAPK signaling downregulates ACE2,^14,15,268 and upregulates ACE,^14,268,269 Ang-II,^89,268,270 ADAM-17,^5,271,272 and IL-6.^114,249,267 It also disrupts endothelial tight-junctions,^45,108,257 and reduces NO bioavailability (via eNOS uncoupling,^113,273,274 decreased NO production,^55,115,267 and NO scavenging^104,109,275). Hyperglycemia-mediated ROS production effectively promotes endothelial dysfunction.^104,108,113 Therefore hyperglycemia increases vascular permeability,^39,115,276 and subsequently promotes (pulmonary) edema.^55,203,277

Hyperglycemia also promotes thrombosis,^24,113,118 via platelet activation, increased coagulation factors, and decreased fibrinolysis.^114,205,278

Furthermore, hyperglycemia (even short-term) dysregulates both the innate and adaptive immune system.^24,55,265 This may affect neutrophil-IL-6 signaling, chemotaxis, phagocytosis, respiratory burst, anti-microbial activity, and production of inflammatory cytokines.^23,55,266 This creates a milieu in which SARS-CoV-2 can flourish.^15,23,24

Finally, hyperglycemia also interferes with the CS, upregulating expression of several CS component genes, hindering C3_b-mediated opsonization and IG-function via glycation.^55,279,280

Well-controlled blood-glucose levels reduce the risk of severe COVID-19 complications.^23,24,281 Therefore, our framework can now be further expanded with the hypothesis: “T2DM-induced hyperglycemia is not only just a risk factor for severe COVID-19 complications, but is actually exacerbated (possibly even induced) by COVID-19.”

Next, the role of IL-6 signaling, and the interactions with T2DM and COVID-19 complications, will be discussed.

Interleukin 6

IL-6 has both pro- and anti-inflammatory characteristics.^53,208,282 Dysregulated or excessive IL-6 signaling is considered to be involved in insulin resistance,^104,206,247 β-cell dysfunction,^53,245,251 T2DM,^53,208,218 and CVD.^208,283,284

Various cell types can locally produce IL-6,^284–286 which can be transported through the circulation, affecting more distant regions in the body.⁵³ Immune cells are simultaneously both sources and targets of IL-6.^53,283,286 Beta-coronavirus infection of immune cells, for example, monocytes, macrophages, and dendritic cells, will result in their activation and subsequent secretion of IL-6.²⁸⁷

To exert its physiological effects, IL-6 utilizes both the classic and trans signaling pathway.^208,213,288 In classic signaling, IL-6 binds to mIL-6R and forms a complex with gp130, after which downstream signaling is mediated via JAK and STAT3.^283,284,286 In trans signaling, extracellular sIL-6R can bind to IL-6, forming a complex with gp130, after which downstream signaling is mediated via JAK and STAT3 in cells that do not express mIL-6R^53,284,289 (such as endothelial^53,116,284 and pancreatic α and β cells^245,246,248). IL-6 classic signaling is mostly involved in anti-inflammatory activities, whereas IL-6 trans signaling is mostly involved in pro-inflammatory activities.^53,213,289

Most cells express gp130, while mIL-6R is mostly found on monocytes, macrophages, neutrophils, and α- and β-cells of pancreatic Langerhans islets.^53,208,245 The widespread expression of gp130 on most cell types, including endothelial cells, dramatically expands the range of IL-6 target cells using trans signaling.^208,284,287 In order to prevent a systemic response to IL-6 trans signaling, sgp130 specifically blocks trans signaling without affecting classical signaling, and basically constitutes a physiological buffer for circulating IL-6.^53,284,288

IL-6 activates ERK_1/2,^54,206,290 JNK,^291–293 and p38-MAPK,^89,294,295 subsequently initiating crosstalk with NF-κB^44,104,249 (Figure 1). This IL-6-mediated MAPK signaling decreases P(Tyr)IRS-1^54,104,247 and increases P(Ser)IRS-1,^206,296,297 inducing insulin resistance^53,89,296 and impairing NO production.^54,206,290 IL-6-mediated MAPK signaling also disrupts endothelial tight-junctions^116,285,298 and induces endothelial cell contraction.^285,299 Therefore, IL-6 effectively increases vascular permeability^70,104,285 and exacerbates edema¹¹⁶ and lung injury/ARDS.^70,300,301 The lack of mIL-6R on endothelial cells indicates trans signaling as the main mechanism involved in the detrimental effects of IL-6 on vasculature.^53,116,284

IL-6 also induces epigenetic changes (regarding genes involved in insulin signaling) via DNMT-induced alteration of DNA methylation patterns, promoting endothelial dysfunction^54,302 and insulin resistance.^213,303,304

IL-6 levels are significantly elevated in COVID-19 patients.^22,305,306 IL-6 plays an important role in CRS,^16,306,307 exacerbates ARDS,^70,287,305 and predicts mortality^282,305,308 (Figure 4).

Figure 4.

The RAAS, CS, KKS, IR, IL-6, and their interactions regarding severe COVID-19 complications, for example, ARDS and thrombosis, with ACE2 as master regulator.

Our framework can now be further expanded with the hypothesis: “Excessive IL-6 trans signaling significantly contributes to severe COVID-19 complications.”

In the last section, we will briefly discuss some potential attractive therapeutic targets and their pharmacological interactions.

Pharmacological interactions

Due to the lack of approved targeted medication for COVID-19,^16,22,309 and developing an effective and safe vaccine may require some time, it is recommended to explore multiple potential therapeutic targets to mitigate severe COVID-19 complications.

TMPRSS2 inhibition

Since TMPRSS2 is essential for SARS-CoV-2 membrane fusion and subsequent cell-entry,^2,3,7 inhibition of TMPRSS2 activity can potentially prevent severe COVID-19 complications.^3,8,310 Nafamostat Mesylate, a clinically approved and safe medication for pancreatitis, inhibits TMPRSS2-mediated SARS-CoV-2 envelope-membrane fusion and subsequent cell-entry.^3,311,312 Nafamostat Mesylate may also protect against thrombosis and DIC via its anti-coagulant properties.^3,313

ACE inhibition/angiotensin II receptor blockage

Both ACE-inhibitors and ARBs reduce hypertension,^85,96,129 CVD,^80,96,129 pneumonia,^314–316 insulin resistance (and T2DM).^85,86,106 They also increase ACE2 expression^1,76,80 and mitigate pulmonary edema.^71,317,318 ACE-inhibitors however, also inhibit BK degradation, subsequently increasing BK, possibly increasing vascular permeability^75,107,149 and systemic acquired angioedema.^75,149,319

Because ACE-inhibitors and ARBs upregulate ACE2 expression,^1,76,80 and SARS-CoV-2 uses ACE2 for cell-entry,^3,6,8 it has been speculated that ACE-inhibitors and ARBs can have negative effects in COVID-19 patients.^140–142 Multiple studies however, show no association between both ACE-inhibitors and ARBs, and increased susceptibility for COVID-19 or the severity of its complications.^320–322

Various experimental models^37,71,76 show that rhsACE2 activates the protective ACE2/Ang-(1-7)/MasR-axis of the RAAS,^71,76,80 degrades des-Arg⁹-BK,⁷⁵ and improves ARDS symptoms.^44,71,82 Therapeutic use of rhsACE2 in COVID-19 patients may have beneficial effects, such as effectively sequestering circulating viral particles to prevent S-protein interactions with membrane-bound ACE2, while simultaneously rebalancing the RAAS into a more protective equilibrium.^6,76,323 Clinical-grade rhsACE2 can significantly inhibit SARS-CoV-2 infections in vitro (in a dose-dependent manner), reduce viral load by a factor of 1.000 – 5.000,³²⁴ and is currently being tested in a phase-II trial in Europe.^5,127

Complement/kinin inhibition

Inhibiting an excessively active CS may reduce severe COVID-19 complications, for example, ARDS,¹⁵³ pulmonary fibrosis,^50,154 (diffuse) TMA,^159,171 and DIC.^74,151,153 Eculizumab is a monoclonal antibody that binds to C5 and prevents cleavage into C5_a and C5_b, as well as the formation of the C5_b-C9 MAC,^16,74,325 and may also reduce the risk of TMA^162,163,165 and DIC.^166,326

Inhibiting the KKS, either by inhibiting kinin production or blocking B1R/B2R, may improve COVID-19-induced ARDS.^25,75,327 Since B1R is upregulated during inflammation,^56,107,180 and des-Arg⁹-BK is much more stable than BK,^148,164 the des-Arg⁹-BK/B1R axis is of major importance in vascular permeability during inflammation.¹⁶⁴ Unfortunately, there currently is no approved B1R-inhibitor available.^25,75,327 Icatibant is a selective B2R antagonist, traditionally used for hereditary angioedema,^25,107,164 and may improve severe COVID-19 complications.^75,327 B2R inhibition, besides reducing the KKS, also reduces the CS.¹⁴⁸

C1_INH inhibits the activation of both the CS and KKS,¹⁴⁸ qualifying it as an attractive potential therapeutic option for severe COVID-19 complications. Plasma-derived C1_INH, a first-line therapy for hereditary angioedema, appears to be safe.³²⁸ Ruconest, a recombinant human C1-esterase-inhibitor, has achieved some good preliminary results in treating COVID-19 patients, according to a press release.³²⁹

Interleukin 6 inhibition

IL-6 inhibition mitigates vascular permeability and alveolar-capillary barrier disruption.^70,116,309

Tocilizumab is a monoclonal antibody, mainly used for the treatment of rheumatoid arthritis.^22,308,330 It inhibits IL-6^305,306,331 via binding to both mIL-6R and sIL-6R, resulting in complete blockade of both classic and trans IL-6 signaling pathways.^287,308,330 Disruption of both pro- and anti-inflammatory activities of IL-6 may cause side-effects, for example, secondary (bacterial or fungal) infections, liver malfunction, or hypercholesterolemia.^53,208 Despite the possible side-effects, preliminary studies show that Tocilizumab appears to be effective and safe regarding severe COVID-19 complications.^22,306,309 Tocilizumab however, seems less effective in hyperglycemic patients.³³²

Sgp130Fc (a recombinant version of sgp130) specifically blocks IL-6 trans signaling, without affecting the anti-inflammatory and protective classical IL-6 signaling.^53,208,288 Therefore sgp130Fc may result in better therapeutic outcomes with fewer undesired side-effects.^53,208,333 Sgp130Fc has demonstrated robust efficacy in the treatment of several autoimmune and inflammatory conditions^53,288 with fewer side-effects than global IL-6-inhibitors.^53,208,333 Sgp130Fc may potentially have therapeutic benefits for COVID-19-induced ARDS.³³³

Summary

We have established the concluding framework regarding the COVID-19 pathophysiological crossroads: “COVID-19 disrupts the RAAS balance via reduction of ACE2 expression and a subsequent elevation of Ang-II. COVID-19-induced reduction of ACE2 expression induces excessive activation of the KKS and subsequently the CS. T2DM-induced hyperglycemia is not only just a risk factor for severe COVID-19 complications, but is actually exacerbated (possibly even induced) by COVID-19. Ang-II, excessive KKS and CS activation, hyperglycemia, and IL-6 trans signaling, all contribute significantly to severe COVID-19 complications (e.g. ARDS and thrombosis/DIC).” The RAAS, CS, KKS, and the coagulation pathway, are all intrinsically connected sensitive systems, with ACE2 as master regulator. Elevated ACE2 baseline levels may protect from severe COVID-19 complications.

There are no effective approved medications against COVID-19 yet, and a vaccine may be a long way off. However, several attractive therapeutic targets in the RAAS, CS, and KKS have shown promising preliminary results against severe COVID-19 complications.

Footnotes

Appendix

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Martijn Hoevenaar

Dolf Goossens

Janne Roorda

References

Kakodkar

Kaka

Baig

A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus 2020; 12(4): e7560.

Lukassen

Chua

Trefzer

, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J 2020; 39(10): e105114.

Xiao

Sakagami

Miwa

ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel?

Viruses 2020; 12(5): 491.

Chen

Jiang

Xia

, et al. Individual variation of the SARS-CoV2 receptor ACE2 gene expression and regulation. Aging Cell 2020; 19(7): e13168.

Gheblawi

Wang

Viveiros

, et al. Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 2020; 126(10): 1456–1474.

Verdecchia

Cavallini

Spanevello

, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020; 76: 14–20.

Hoffmann

Kleine-Weber

Schroeder

, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271–280.

Stopsack

Mucci

Antonarakis

, et al. TMPRSS2 and COVID-19: serendipity or opportunity for intervention? Cancer Discov 2020; 10: 1–4.

Huang

Wang

, et al. ACE2 shedding and furin abundance in target organs may influence the efficiency of SARS-CoV-2 entry. ChinaXiv 2020; 202002.00082v1.

10.

Patel

Clarke

Wang

, et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 2014; 66: 167–176.

11.

Lin

Ferguson

White

, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59(17): 4180–4184.

12.

Corley

Ndhlovu

LC.

DNA methylation analysis of the COVID-19 host cell receptor, angiotensin I converting enzyme 2 gene (ACE2) in the respiratory system reveal age and gender differences. Preprints 2020; 2020030295.

13.

Pruimboom

Methylation pathways and SARS-CoV-2 lung infiltration and cell membrane-virus fusion are both subject to epigenetics. Front Cell Infect Microbiol 2020; 10: 290.

14.

Lin

Gao

Zhao

, et al. Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease. Mol Biol Rep 2016; 43(5): 397–406.

15.

Pal

Bhansali

COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract 2020; 162: 108132.

16.

Diurno

Numis

Porta

, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 2020; 24(7): 4040–4047.

17.

Huang

Wang

, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497–506.

18.

Brann

Tsukahara

Weinreb

, et al. Non-neural expression of SARS-CoV-2 entry genes in the olfactory epithelium suggests mechanisms underlying anosmia in COVID-19 patients. BioRxiv 2020.

19.

Lechien

Chiesa-Estomba

De Siati

, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020; 277: 2251–2261.

20.

Vaira

Salzano

Deiana

, et al. Anosmia and ageusia: common findings in COVID-19 patients. Laryngoscope 2020; 130: 1787.

21.

Henry

Vikse

Benoit

, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020; 507: 167–173.

22.

Han

, et al. Effective treatment of severe COVID-19 patients with tocilizumab. PNAS 2020; 117(20): 10970–10975.

23.

Zhu

She

Cheng

, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31(6): 1068–1077.e3.

24.

Wang

Zhu

Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 2020; 164: 108214.

25.

Tolouian

Vahed

Ghiyasvand

, et al. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Inj Prev 2020; 9(2): e19.

26.

Channappanavar

Perlman

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39(5): 529–539.

27.

Mosaddeghi

Negahdaripour

Dehghani

, et al. Therapeutic approaches for COVID-19 based on the dynamics of interferon-mediated immune responses. Preprints 2020; 2020030206.

28.

Prompetchara

Ketloy

Palaga

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38: 1–9.

29.

Zheng

Gao

Wang

, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17: 533–535.

30.

Abdulamir

Hafidh

RR.

The possible immunological pathways for the variable immunopathogenesis of COVID-19 infections among healthy adults, elderly and children. Electron J Gen Med 2020; 17(4): em202.

31.

Deng

Pei

Regulation of interferon production as a potential strategy for COVID-19 treatment. arXiv 2020; 2003.00751.

32.

Qin

Zhou

, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis 2020; 71(15): 762–768.

33.

Ruan

Yang

Wang

, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846–848.

34.

Zhang

Wang

, et al. Potential factors for prediction of disease severity of COVID-19 patients. medRxiv 2020.

35.

Imai

Kuba

Rao

, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436(7047): 112–116.

36.

Imai

Kuba

Penninger

JM.

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp Physiol 2008; 93(5): 543–548.

37.

Kuba

Imai

Penninger

JM.

Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006; 6(3): 271–276.

38.

Bao

Gao

Xie

, et al. Angiotensin-converting enzyme 2 inhibits apoptosis of pulmonary endothelial cells during acute lung injury through suppressing MiR-4262. Cell Physiol Biochem 2015; 37(2): 759–767.

39.

Barabutis

Verin

Catravas

JD.

Regulation of pulmonary endothelial barrier function by kinases. Am J Physiol Lung Cell Mol Physiol 2016; 311(5): L832–L845.

40.

Lai

Qiu

Chen

, et al. Inhibition of c-Jun N-terminal kinase signaling pathway alleviates lipopolysaccharide-induced acute respiratory distress syndrome in rats. Chin Med J (Engl) 2016; 129(14): 1719–1724.

41.

Deng

Wang

Deng

, et al. The effect of endogenous angiotensin II on alveolar fluid clearance in rats with acute lung injury. Can Respir J 2012; 19(5): 311–318.

42.

Herrero

Sanchez

Lorente

JA.

New insights into the mechanisms of pulmonary edema in acute lung injury. Ann Transl Med 2018; 6(2): 32.

43.

Lin

Qin

, et al. ACE2 antagonizes VEGFa to reduce vascular permeability during acute lung injury. Cell Physiol Biochem 2016; 38(3): 1055–1062.

44.

Cao

Zeng

, et al. Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-κB pathways. Sci Rep 2015; 5: 8209.

45.

, et al. P38/MAPK contributes to endothelial barrier dysfunction via MAP4 phosphorylation-dependent microtubule disassembly in inflammation-induced acute lung injury. Sci Rep 2015; 5: 8895.

46.

Millar

Summers

Griffiths

, et al. The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. Thorax 2016; 71(5): 462–473.

47.

Frantzeskaki

Armaganidis

Orfanos

SE.

Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration 2017; 93(3): 212–225.

48.

Rusu

Minshall

RD.

Endothelial cell von Willebrand factor secretion in health and cardiovascular disease. In: Lenasi H (ed.) Endothelial dysfunction: old concepts and new challenges. 1st ed. London: IntechOpen, 2018, p.147.

49.

Cardinal-Fernández

Lorente

Ballén-Barragán

, et al. Acute respiratory distress syndrome and diffuse alveolar damage. New insights on a complex relationship. Ann Am Thorac Soc 2017; 14(6): 844–850.

50.

Silasi-Mansat

Zhu

Georgescu

, et al. Complement inhibition decreases early fibrogenic events in the lung of septic baboons. J Cell Mol Med 2015; 19(11): 2549–2563.

51.

Radermacher

Maggiore

Mercat

Fifty years of research in ARDS. Gas exchange in acute respiratory distress syndrome. Am J Respir Crit Care Med 2017; 196(8): 964–984.

52.

Zhang

Baker

Recombinant human ACE2: acing out angiotensin II in ARDS therapy. Crit Care 2017; 21: 305.

53.

Akbari

Hassan-Zadeh

IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology 2018; 26(3): 685–698.

54.

Balakrishnan

Guruprasad

Satyamoorthy

, et al. Interleukin-6 determines protein stabilization of DNA methyltransferases and alters DNA promoter methylation of genes associated with insulin signaling and angiogenesis. Lab Invest 2018; 98(9): 1143–1158.

55.

Jafar

Edriss

Nugent

The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci 2016; 351(2): 201–211.

56.

Sodhi

Wohlford-Lenane

Yamaguchi

, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg⁹ bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol 2018; 314(1): L17–L31.

57.

Babior

Lambeth

Nauseef

The neutrophil NADPH oxidase. Arch Biochem Biophys 2002; 397(2): 342–344.

58.

Zhang

Kimura

, et al. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res 2007; 76(2): 204–212.

59.

Nguyen

Green

Mecsas

Neutrophils to the ROScue: mechanisms of NADPH oxidase activation and bacterial resistance. Front Cell Infect Microbiol 2017; 7: 373.

60.

Pechous

RD.

With friends like these: the complex role of neutrophils in the progression of severe pneumonia. Front Cell Infect Microbiol 2017; 7: 160.

61.

Sheppard

Kelher

Moore

, et al. Structural organization of the neutrophil NADPH oxidase: phosphorylation and translocation during priming and activation. J Leukoc Biol 2005; 78(5): 1025–1042.

62.

Hamacher

Hadizamani

Borgmann

, et al. Cytokine-ion channel interactions in pulmonary inflammation. Front Immunol 2018; 8: 1644.

63.

Trac

Thai

Linck

, et al. Alveolar nonselective channels are ASIC1a/α-ENaC channels and contribute to AFC. Am J Physiol Lung Cell Mol Physiol 2017; 312(6): L797–L811.

64.

Jia

Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 2016; 46(3): 239–248.

65.

Alexander

Elrod

JW.

Extracellular matrix, junctional integrity and matrix metalloproteinase interactions in endothelial permeability regulation. J Anat 2002; 200(6): 561–574.

66.

Pelosi

Rocco

Negrini

, et al. The extracellular matrix of the lung and its role in edema formation. An Acad Bras Cienc 2007; 79(2): 285–297.

67.

Kulkarni

De Andrade

Zhou

, et al. Alveolar epithelial disintegrity in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2016; 311(2): L185–L191.

68.

Parimon

Yao

Stripp

, et al. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci 2020; 21(7): 2269.

69.

Araya

Nishimura

SL.

Fibrogenic reactions in lung disease. Annu Rev Pathol 2010; 5: 77–98.

70.

Gurkan

Zielinski

, et al. Interleukin-6 mediates pulmonary vascular permeability in a two-hit model of ventilator-associated lung injury. Exp Lung Res 2011; 37(10): 575–584.

71.

Wang

Chai

Magnnusen

, et al. Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation. Pulm Pharmacol Ther 2019; 58: 101833.

72.

Cohen

Lawrence

Khasgiwala

, et al. MAPK activation modulates permeability of isolated rat alveolar epithelial cell monolayers following cyclic stretch. PLoS One 2010; 5(4): e10385.

73.

Gattinoni

Chiumello

Rossi

COVID-19 pneumonia: ARDS or not?

Crit Care 2020; 24: 154.

74.

Magro

Mulvey

Berlin

, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1–13.

75.

Van De Veerdonk

Netea

Van Deuren

, et al. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife 2020; 9: e57555.

76.

Guo

Huang

Lin

, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc 2020; 9(7): e016219.

77.

Iwai

Horiuchi

. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT 1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res 2009; 32(7): 533–536.

78.

Lovren

Pan

Quan

, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008; 295(4): H1377–H1384.

79.

Tassone

Sciacqua

Andreozzi

, et al. Angiotensin (1-7) counteracts the negative effect of angiotensin II on insulin signalling in HUVECs. Cardiovasc Res 2013; 99(1): 129–136.

80.

Gromotowicz-Poplawska

Szoka

Kolodziejczyk

, et al. New agents modulating the renin-angiotensin-aldosterone system—will there be a new therapeutic option? Exp Biol Med 2016; 241(17): 1888–1899.

81.

Imai

Kuba

Penninger

JM.

Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci 2007; 64(15): 2006–2012.

82.

Tikellis

Thomas

Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept 2012; 2012: 256294.

83.

Bodor

Nagy

Végh

, et al. Angiotensin II increases the permeability and PV-1 expression of endothelial cells. Am J Physiol Cell Physiol 2012; 302(1): C267–C276.

84.

Imai

Kuba

Ohto-Nakanishi

, et al. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J 2010; 74(3): 405–410.

85.

Damas

Garbacki

Lefebvre

The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity. Diabetes Metab Res Rev 2004; 20(4): 288–297.

86.

Wei

Sowers

Clark

, et al. Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-κB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2008; 294(2): E345–E351.

87.

Motley

Eguchi

Gardner

, et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-α. Hypertension 2003; 41(3): 775–780.

88.

Muscogiuri

Chavez

Gastaldelli

, et al. The crosstalk between insulin and renin-angiotensin-aldosterone signaling systems and its effect on glucose metabolism and diabetes prevention. Curr Vasc Pharmacol 2008; 6(4): 301–312.

89.

Olivares-Reyes

Arellano-Plancarte

Castillo-Hernandez

JR.

Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 2009; 302(2): 128–139.

90.

Ebrahimian

Lemarié

, et al. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 2011; 57(2): 245–254.

91.

Wen

Gwathmey

Xie

LH.

Oxidative stress-mediated effects of angiotensin II in the cardiovascular system. World J Hypertens 2012; 2(4): 34–44.

92.

Dikalov

Nazarewicz

RR.

Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease. Antioxid Redox Signal 2013; 19(10): 1085–1094.

93.

Izawa

Yoshizumi

Fujita

, et al. ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells. Exp Cell Res 2005; 308(2): 291–299.

94.

Andreozzi

Laratta

Sciacqua

, et al. Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells. Circ Res 2004; 94(9): 1211–1218.

95.

Oudit

Kassiri

Patel

, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc Res 2007; 75(1): 29–39.

96.

Eguchi

Dempsey

Frank

, et al. Activation of MAPKs by angiotensin II in vascular smooth muscle cells metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem 2001; 276(11): 7957–7962.

97.

De Fea

Roth

. Modulation of insulin receptor substrate-1 tyrosine phosphorylation and function by mitogen-activated protein kinase. J Biol Chem 1997; 272(50): 31400–31406.

98.

Guo

Yang

, et al. Emerging role of the Jun N-terminal kinase interactome in human health. Cell Biol Int 2018; 42(7): 756–768.

99.

Yung

JHM

Giacca

. Role of c-Jun N-terminal kinase (JNK) in obesity and type 2 diabetes. Cells 2020; 9(3): 706.

100.

Harper

Woodcock

Lam

, et al. Temperature regulates NF-κB dynamics and function through timing of A20 transcription. Proc Natl Acad Sci USA 2018; 115(22): E5243–E5249.

101.

Pires

Silva

Ferreira

, et al. NF-kappaB: two sides of the same coin. Genes (Basel) 2018; 9(1): 24.

102.

Anrather

Racchumi

Iadecola

NF-κB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem 2006; 281(9): 5657–5667.

103.

Manea

Gafencu

, et al. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem 2007; 113(4–5): 163–172.

104.

Saad

Abdelkhalek

Saleh

, et al. Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells. Endocrine 2015; 50(3): 537–567.

105.

Folli

Kahn

Hansen

, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100(9): 2158–2169.

106.

Folli

Saad

Velloso

, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocr Diabetes 1999; 107(2): 133–139.

107.

Bossi

Peerschke

Ghebrehiwet

, et al. Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 2011; 140(1–2): 7–13.

108.

Chattopadhyay

Dyukova

Singh

, et al. Vascular endothelial tight junctions and barrier function are disrupted by 15(S)-hydroxyeicosatetraenoic acid partly via protein kinase C-mediated zona occludens-1 phosphorylation at threonine 770/772. J Biol Chem 2014; 289(6): 3148–3163.

109.

Loscalzo

Oxidative stress in endothelial cell dysfunction and thrombosis. Pathophysiol Haemost Thromb 2002; 32(5–6): 359–360.

110.

Yau

Teoh

Verma

Endothelial cell control of thrombosis. BMC Cardiovasc Disord 2015; 15(1): 130.

111.

Tang

Bai

Chen

, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18(5): 1094–1099.

112.

Dimmeler

Fleming

Fisslthaler

, et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399(6736): 601–605.

113.

Setter

Campbell

Cahoon

CJ.

Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother 2003; 37(12): 1858–1866.

114.

Pechlivani

Ajjan

RA.

Thrombosis and vascular inflammation in diabetes: mechanisms and potential therapeutic targets. Front Cardiovasc Med 2018; 5: 1.

115.

Fouty

Diabetes and the pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 2008; 295(5): L725–L726.

116.

Alsaffar

Martino

Garrett

, et al. Interleukin-6 promotes a sustained loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation and de novo protein synthesis. Am J Physiol Cell Physiol 2018; 314(5): C589–C602.

117.

Lee

Slutsky

AS.

Sepsis and endothelial permeability. N Engl J Med 2010; 363(7): 689–691.

118.

Madamanchi

Hakim

Runge

Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005; 3(2): 254–267.

119.

Escher

Breakey

Lämmle

Severe COVID-19 infection associated with endothelial activation. Thromb Res 2020; 190: 62.

120.

Zachariah

Nair

Goel

, et al. Targeting raised von Willebrand factor levels and macrophage activation in severe COVID-19: consider low volume plasma exchange and low dose steroid. Thromb Res 2020; 192: 2.

121.

Franchini

Capra

Targher

, et al. Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. Thromb J 2007; 5(1): 14.

122.

Zhao

Yang

Huang

, et al. Relationship between the ABO blood group and the COVID-19 susceptibility. Clin Infect Dis. Epub ahead of print August 2020. DOI: 10.1093/cid/ciaa1150.

123.

Shatanawi

Lemtalsi

Yao

, et al. Angiotensin II limits NO production by upregulating arginase through a p38 MAPK-ATF-2 pathway. Eur J Pharmacol 2015; 746: 106–114.

124.

Deng

Wang

Deng

, et al. Regulation of alveolar fluid clearance and ENaC expression in lung by exogenous angiotensin II. Respir Physiol Neurobiol 2012; 181(1): 53–61.

125.

Silhol

Sarlon

Deharo

, et al. Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system? Hypertens Res 2020; 43: 854–856.

126.

Chappel

Ferrario

ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney Int 2006; 70(1): 8–10.

127.

Alhenc-Gelas

Drueke

TB.

Blockade of SARS-CoV-2 infection by recombinant soluble ACE2. Kidney Int 2020; 97(6): 1091–1093.

128.

Jia

Look

Tan

, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol 2009; 297(1): L84–L96.

129.

Hamming

Cooper

Haagmans

, et al. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212(1): 1–11.

130.

Lei

Qian

, et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. Biorxiv 2020.

131.

Gupte

Thatcher

Boustany-Kari

, et al. Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. Arterioscler Thromb Vasc Biol 2012; 32(6): 1392–1399.

132.

Cao

Yang

Xin

, et al. The ACE2/Ang-(1-7)/Mas axis can inhibit hepatic insulin resistance. Mol Cell Endocrinol 2014; 393(1–2): 30–38.

133.

Chhabra

Chodavarapu

Lazartigues

Angiotensin converting enzyme 2: a new important player in the regulation of glycemia. IUBMB Life 2013; 65(9): 731–738.

134.

Cheng

Wang

GQ.

Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 2020; 92(7): 726–730.

135.

Yang

Chu

Rump

, et al. ACE2 and the homolog collectrin in the modulation of nitric oxide and oxidative stress in blood pressure homeostasis and vascular injury. Antioxid Redox Signal 2017; 26(12): 645–659.

136.

Fraga-Silva

Sorg

Wankhede

, et al. ACE2 activation promotes antithrombotic activity. Mol Med 2010; 16(5): 210–215.

137.

Cui

Hou

, et al. Angiotensin-converting enzyme 2-angiotensin (1-7)-Mas axis prevents pancreatic acinar cell inflammatory response via inhibition of the p38 mitogen-activated protein kinase/nuclear factor-κB pathway. Int J Mol Med 2018; 41(1): 409–420.

138.

Gwathmey-Williams

Pendergrass

Rose

, et al. Angiotensin-(1-7)-ACE2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 2010; 55(1): 166.

139.

Xia

Suda

Bindom

, et al. ACE2-mediated reduction of oxidative stress in the central nervous system is associated with improvement of autonomic function. PLoS One 2011; 6(7): e22682.

140.

AlGhatrif

Cingolani

Lakatta

EG.

The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol 2020; 5(7): 747–748.

141.

Bastolla

The differential expression of the ACE2 receptor across ages and gender explains the differential lethality of SARS-Cov-2 and suggests possible therapy. Preprint arXiv: 200407224 2020.

142.

Jarcho

Ingelfinger

Hamel

, et al. Inhibitors of the renin-angiotensin-aldosterone system and Covid-19. N Engl J Med 2020; 382: 2462–2464.

143.

Xudong

Junzhu

Xingxiang

, et al. Age-and gender-related difference of ACE2 expression in rat lung. Life Sci 2006; 78(19): 2166–2171.

144.

Gemmati

Bramanti

Serino

, et al. COVID-19 and individual genetic susceptibility/receptivity: role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int J Mol Sci 2020; 21(10): 3474.

145.

Petkovich

Podolskiy

Lobanov

, et al. Using DNA methylation profiling to evaluate biological age and longevity interventions. Cell Metab 2017; 25(4): 954–960.

146.

Salameh

Bejaoui

El Hajj

DNA methylation biomarkers in aging and age-related diseases. Front Genet 2020; 11: 171.

147.

Lauc

Sinclair

Biomarkers of biological age as predictors of COVID-19 disease severity. Aging 2020; 12(8): 6490–6491.

148.

Fagerström

Ståhl

Mossberg

, et al. Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. EBioMedicine 2019; 47: 319–328.

149.

Kaplan

Ghebrehiwet

The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47(13): 2161–2169.

150.

Amara

Rittirsch

Flierl

, et al. Interaction between the coagulation and complement system. In: Lambris

(ed.) Current topics in complement II. New York: Springer, 2008, Vol. 632, pp.68–76.

151.

Oikonomopoulou

Ricklin

Ward

, et al. Interactions between coagulation and complement-their role in inflammation. Semin Immunopathol 2012; 34(1): 151–165.

152.

Amara

Flierl

Rittirsch

, et al. Molecular intercommunication between the complement and coagulation systems. Semin Immunopathol 2010; 185(9): 5628–5636.

153.

Gao

Zhang

, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv 2020.

154.

Pandya

Wilkes

DS.

Complement system in lung disease. Am J Respir Cell Mol Biol 2014; 51(4): 467–473.

155.

Rothman

Merrow

Bamba

, et al. Biosynthesis of the third and fifth complement components by isolated human lung cells. Am Rev Respir Dis 1989; 139(1): 212–220.

156.

Strunk

Eidlen

Mason

RJ.

Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J Clin Invest 1988; 81(5): 1419–1426.

157.

Czermak

Lentsch

Bless

, et al. Synergistic enhancement of chemokine generation and lung injury by C5a or the membrane attack complex of complement. Am J Pathol 1999; 154(5): 1513–1524.

158.

Williams

Vascular permeability changes induced by complement-derived peptides. Agents Actions 1983; 13(5–6): 451–455.

159.

Campbell

Kahwash

Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis?

Circulation 2020; 141(22): 1739–1741.

160.

Kolev

Le Friec

Kemper

Complement-tapping into new sites and effector systems. Nat Rev Immunol 2014; 14(12): 811–820.

161.

Kenawy

Boral

Bevington

Complement-coagulation cross-talk: a potential mediator of the physiological activation of complement by low pH. Front Immunol 2015; 6: 215.

162.

Hofer

Rosales

Fischer

, et al. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr 2014; 2: 97.

163.

Brocklebank

Kavanagh

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017; 10(5): 600–624.

164.

Charignon

Späth

Martin

, et al. Icatibant, the bradykinin B2 receptor antagonist with target to the interconnected kinin systems. Expert Opin Pharmacother 2012; 13(15): 2233–2247.

165.

Park

Caselman

Ulmer

, et al. Complement-mediated thrombotic microangiopathy associated with lupus nephritis. Blood Adv 2018; 2(16): 2090–2094.

166.

Kurosawa

Stearns-Kurosawa

DJ.

Complement, thrombotic microangiopathy and disseminated intravascular coagulation. J Intensive Care 2014; 2: 65.

167.

Srichaikul

Puwasatien

, et al. Complement changes and disseminated intravascular coagulation in Plasmodium falciparum malaria. Lancet 1975; 305(7910): 770–772.

168.

Mickler

Cummings

, et al. Crosstalk between TGF-β1 and complement activation augments epithelial injury in pulmonary fibrosis. FASEB J 2014; 28(10): 4223–4234.

169.

Meliconi

Senaldi

Sturani

, et al. Complement activation products in idiopathic pulmonary fibrosis: relevance of fragment Ba to disease severity. Clin Immunol Immunopathol 1990; 57(1): 64–73.

170.

Ciceri

Beretta

Scandroglio

, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 2020; 22(2): 95–97.

171.

Gavriilaki

Brodsky

RA.

Severe COVID-19 infection and thrombotic microangiopathy: success doesn’t come easily. Br J Haematol 2020; 189(6): e222–e265.

172.

Oehmcke-Hecht

Köhler

Interaction of the human contact system with pathogens—an update. Front Immunol 2018; 9: 312.

173.

The plasma contact system as a modulator of innate immunity. Curr Opin Hematol 2018; 25(5): 389–394.

174.

Ehrenfeld

Millan

Matus

, et al. Activation of kinin B1 receptors induces chemotaxis of human neutrophils. J Leukoc Biol 2006; 80(1): 117–124.

175.

Mohammed

Matafonov

Ivanov

, et al. An update on factor XI structure and function. Thromb Res 2018; 161: 94–105.

176.

Kaplan

Joseph

Complement, kinins, and hereditary angioedema: mechanisms of plasma instability when C1 inhibitor is absent. Clin Rev Allergy Immunol 2016; 51(2): 207–215.

177.

Sealey

Atlas

Laragh

, et al. Human urinary kallikrein converts inactive to active renin and is a possible physiological activator of renin. Nature 1978; 275(5676): 144–145.

178.

Yokosawa

Takahashi

Inagami

, et al. Isolation of completely inactive plasma prorenin and its activation by kallikreins: a possible new link between renin and kallikrein. Biochim Biophys Acta 1979; 569(2): 211–219.

179.

Cyr

Lepage

Blais

Jr , et al. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. Am J Physiol Heart Circ Physiol 2001; 281(1): H275–H283.

180.

Duka

Shenouda

Johns

, et al. Role of the B(2) receptor of bradykinin in insulin sensitivity. Hypertension 2001; 38(6): 1355–1360.

181.

Bernier

Haldar

Michel

Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J Biol Chem 2000; 275(39): 30707–30715.

182.

Christopher

Velarde

Jaffa

AA.

Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of MAP kinase activation. Hypertension 2001; 38(3): 602–605.

183.

Yiu

Wong

Chan

, et al. Tissue kallikrein mediates pro-inflammatory pathways and activation of protease-activated receptor-4 in proximal tubular epithelial cells. PLoS One 2014; 9(2): e88894.

184.

Tidjane

Gaboury

Couture

Cellular localisation of the kinin B1R in the pancreas of streptozotocin-treated rat and the anti-diabetic effect of the antagonist SSR240612. Biol Chem 2016; 397(4): 323–336.

185.

Zuccollo

Navarro

Frontera

, et al. The involvement of kallikrein-kinin system in diabetes type I (insulitis). Immunopharmacology 1999; 45(1–3): 69–74.

186.

Schmaier

AH.

A novel antithrombotic mechanism mediated by the receptors of the kallikrein/kinin and renin-angiotensin systems. Front Med (Lausanne) 2016; 3: 61.

187.

Contact pathway of coagulation and inflammation. Thromb J 2015; 13(1): 17.

188.

Schmaier

AH.

Physiologic activities of the contact activation system. Thromb Res 2014; 133: S41–S44.

189.

Ruiz

Vardon-Bounes

Buléon

, et al. Kinin B1 receptor: a potential therapeutic target in sepsis-induced vascular hyperpermeability. J Transl Med 2020; 18: 174.

190.

Irmscher

Döring

Halder

, et al. Kallikrein cleaves C3 and activates complement. J Innate Immun 2018; 10(2): 94–105.

191.

Oikonomopoulou

DeAngelis

Chen

, et al. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. J Immunol 2013; 191(7): 3858–3866.

192.

Bossi

Fischetti

Durigutto

, et al. The terminal complement complex induces vascular leakage: in vitro and in vivo evidence. In: 9th European meeting on complement in human disease (eds MR

Daha

CJM

Melief

), Trieste, Italy, 2003, pp.178–179.

193.

Bossi

Fischetti

Pellis

, et al. Platelet-activating factor and kinin-dependent vascular leakage as a novel functional activity of the soluble terminal complement complex. J Immunol 2004; 173(11): 6921–6927.

194.

Varagic

Ahmad

Nagata

, et al. ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014; 16(3): 420.

195.

Bernstein

Moellman

Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med 2012; 5(1): 39.

196.

Craig

Bernstein

Farkas

, et al. Diagnosis and treatment of bradykinin-mediated angioedema: outcomes from an angioedema expert consensus meeting. Int Arch Allergy Immunol 2014; 165(2): 119–127.

197.

Depetri

Tedeschi

Cugno

Angioedema and emergency medicine: from pathophysiology to diagnosis and treatment. Eur J Intern Med 2019; 59: 8–13.

198.

Luo

Wead

Yang

, et al. Nitric oxide mediates C5a-induced vasodilation in the small intestine. Microcirculation 1995; 2(1): 53–61.

199.

Hameed

Masoodi

Mir

, et al. Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes 2015; 6(4): 598–612.

200.

Stampfer

Haffner

, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25(7): 1129–1134.

201.

Hassing

Hofer

Nilsson

, et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004; 33(4): 355–361.

202.

Hurst

Thinkhamrop

Tran

HT.

The association between hypertension comorbidity and microvascular complications in type 2 diabetes patients: a nationwide cross-sectional study in Thailand. Diabetes Metab J 2015; 39(5): 395–404.

203.

Clemmer

Xiang

, et al. Hyperglycemia-mediated oxidative stress increases pulmonary vascular permeability. Microcirculation 2016; 23(3): 221–229.

204.

Kassab

McFarlane

Sowers

Vascular complications in diabetes and their prevention. Vasc Med 2001; 6(4): 249–255.

205.

Stegenga

Van Der Crabben

Levi

, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55(6): 1807–1812.

206.

Andreozzi

Laratta

Procopio

, et al. Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 2007; 27(6): 2372–2383.

207.

Stern

MP.

Diabetes and cardiovascular disease: the “common soil” hypothesis. Diabetes 1995; 44(4): 369–374.

208.

Liu

Lau

, et al. IL-6 in diabetes and cardiovascular complications. Br J Pharmacol 2014; 171(15): 3595–3603.

209.

Ziegler

Type 2 diabetes as an inflammatory cardiovascular disorder. Curr Mol Med 2005; 5(3): 309–322.

210.

Adeva-Andany

Martínez-Rodríguez

González-Lucán

, et al. Insulin resistance is a cardiovascular risk factor in humans. Diabetes Metab Syndr 2019; 13(2): 1449–1455.

211.

Johnson

Olefsky

JM.

The origins and drivers of insulin resistance. Cell 2013; 152(4): 673–684.

212.

Ehses

Perren

Eppler

, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 2007; 56(9): 2356–2370.

213.

Shi

Fan

, et al. Cytokines and abnormal glucose and lipid metabolism in type 2 diabetes. Front Endocrinol 2019; 10: 703.

214.

Ying

Lee

, et al. The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities. Nat Rev Endocrinol 2019; 16: 81–90.

215.

Lumeng

Bodzin

Saltiel

AR.

Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117(1): 175–184.

216.

Pereira

Alvarez-Leite

JI.

Low-grade inflammation, obesity, and diabetes. Curr Obes Rep 2014; 3(4): 422–431.

217.

Han

White

Perry

, et al. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci USA 2020; 117(6): 2751–2760.

218.

Klover

Zimmers

Koniaris

, et al. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003; 52(11): 2784–2789.

219.

Samaras

Botelho

Chisholm

, et al. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring) 2010; 18(5): 884–889.

220.

Mancini

White

Bijland

, et al. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol Cell Endocrinol 2017; 440: 44–56.

221.

Lanuza-Masdeu

Arévalo

Vila

, et al. In vivo JNK activation in pancreatic β-cells leads to glucose intolerance caused by insulin resistance in pancreas. Diabetes 2013; 62(7): 2308–2317.

222.

Frigolet

Torres

Tovar

AR.

The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity. J Nutr Biochem 2013; 24(12): 2003–2015.

223.

Marcus

Shefer

Stern

Adipose tissue renin-angiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol 2013; 378(1–2): 1–14.

224.

Esposito

Cama

, et al. Tyr612 and Tyr632 in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 2001; 142(7): 2833–2840.

225.

Fulton

Gratton

McCabe

, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399(6736): 597–601.

226.

Zeng

Nystrom

Ravichandran

, et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 2000; 101(13): 1539–1545.

227.

Gewaltig

Kojda

Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 2002; 55(2): 250–260.

228.

Yasa

Türkseven

Vasoprotective effects of nitric oxide in atherosclerosis. FABAD J Pharm Sci 2005; 30(1): 41.

229.

Versari

Daghini

Virdis

, et al. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32(suppl 2): S314–S321.

230.

Aguirre

Uchida

Yenush

, et al. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J Biol Chem 2000; 275(12): 9047–9054.

231.

Richey

JM.

The vascular endothelium, a benign restrictive barrier? No! Role of nitric oxide in regulating insulin action. Diabetes 2013; 62(12): 4006–4008.

232.

Aguirre

Werner

Giraud

, et al. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002; 277(2): 1531–1537.

233.

Lee

Giraud

Davis

, et al. c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 2003; 278(5): 2896–2902.

234.

Hong

Lee

Rhee

, et al. Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: possible explanation of islet-specific fibrosis in type 2 diabetes mellitus. J Cell Biochem 2007; 101(3): 665–675.

235.

Wang

Zhu

Zhang

, et al. Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett 2012; 322(2): 223–231.

236.

Pirola

Johnston

Van Obberghen

Modulators of insulin action and their role in insulin resistance. Int J Obes Relat Metab Disord 2003; 27(3): S61–S64.

237.

Giacchetti

Sechi

Rilli

, et al. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 2005; 16(3): 120–126.

238.

Samuelsson

Bollano

Mobini

, et al. Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways. Am J Physiol Heart Circ Physiol 2006; 291(2): H787–H796.

239.

Henriksen

Prasannarong

The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Mol Cell Endocrinol 2013; 378(1–2): 15–22.

240.

Huisamen

Pêrel

Friedrich

, et al. ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem 2011; 349(1–2): 21–31.

241.

Hsueh

Wyne

Renin-angiotensin-aldosterone system in diabetes and hypertension. J Clin Hypertens (Greenwich) 2011; 13(4): 224–237.

242.

Muniyappa

Yavuz

Metabolic actions of angiotensin II and insulin: a microvascular endothelial balancing act. Mol Cell Endocrinol 2013; 378(1–2): 59–69.

243.

Ormazabal

Nair

Elfeky

, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17(1): 122.

244.

Kasuga

Insulin resistance and pancreatic β cell failure. J Clin Invest 2006; 116(7): 1756–1760.

245.

Ellingsgaard

Ehses

Hammar

, et al. Interleukin-6 regulates pancreatic α-cell mass expansion. Proc Natl Acad Sci USA 2008; 105(35): 13163–13168.

246.

Ota

Itaya-Hironaka

Yamauchi

, et al. Pancreatic β cell proliferation by intermittent hypoxia via up-regulation of Reg family genes and HGF gene. Life Sci 2013; 93(18–19): 664–672.

247.

Senn

Klover

Nowak

, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51(12): 3391–3399.

248.

Ellingsgaard

Hauselmann

Schuler

, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011; 17(11): 1481–1489.

249.

Devaraj

Venugopal

Singh

, et al. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-α and-β. Diabetes 2005; 54(1): 85–91.

250.

Esposito

Nappo

Marfella

, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106(16): 2067–2072.

251.

Lee

Park

, et al. Interleukin-6 treatment induces beta-cell apoptosis via STAT-3-mediated nitric oxide production. Diabetes Metab Res Rev 2011; 27(8): 813–819.

252.

Ramalingam

Menikdiwela

LeMieux

, et al. The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance. Bichim Biophys Acta Mol Basis Dis 2017; 1863(5): 1106–1114.

253.

Muniyappa

Quon

MJ.

Insulin action and insulin resistance in vascular endothelium. Curr Opin Clin Nutr 2007; 10(4): 523–530.

254.

Yamagishi

Si.

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011; 46(4): 217–224.

255.

Tilton

RG.

Diabetic vascular dysfunction: links to glucose-induced reductive stress and VEGF. Microsc Res Tech 2002; 57(5): 390–407.

256.

Volpe

CMO

Villar-Delfino

Dos Anjos

PMF

, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis 2018; 9(2): 1–9.

257.

Yuan

Breslin

Perrin

, et al. Microvascular permeability in diabetes and insulin resistance. Microcirculation 2007; 14(4–5): 363–373.

258.

Thallas-Bonke

Thorpe

Coughlan

, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway. Diabetes 2008; 57(2): 460–469.

259.

Kumar

Rao

Pal

, et al. Hyperglycemia-induced oxidative stress induces apoptosis by inhibiting PI3-kinase/Akt and ERK1/2 MAPK mediated signaling pathway causing downregulation of 8-oxoG-DNA glycosylase levels in glial cells. Int J Biochem Cell Biol 2014; 53: 302–319.

260.

Sun

Tong

, et al. The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci 2016; 17(12): 2001.

261.

Jhun

Yoon

High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal 2011; 14(3): 425–437.

262.

Hein

, et al. Acute and chronic hyperglycemia elicit JIP1/JNK-mediated endothelial vasodilator dysfunction of retinal arterioles. Invest Ophthalmol Vis Sci 2016; 57(10): 4333–4340.

263.

Yang

Cao

Hyperglycemia induces iNOS gene expression and consequent nitrosative stress via JNK activation. Am J Obstet Gynecol 2010; 203(2): 185.e5–185.e11.

264.

Igarashi

Wakasaki

Takahara

, et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999; 103(2): 185–195.

265.

Martinez

Vallerskog

West

, et al. Chromatin decondensation and T cell hyperresponsiveness in diabetes-associated hyperglycemia. J Immunol 2014; 193(9): 4457–4468.

266.

Montani

MSG

Granato

Cuomo

, et al. High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/β-catenin and p38 MAPK. Biochim Biophys Acta 2016; 1862(4): 805–813.

267.

Arcambal

Taïlé

Rondeau

, et al. Hyperglycemia modulates redox, inflammatory and vasoactive markers through specific signaling pathways in cerebral endothelial cells: insights on insulin protective action. Free Radic Bio Med 2019; 130: 59–70.

268.

Lavrentyev

Estes

Malik

KU.

Mechanism of high glucose-induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007; 101(5): 455–464.

269.

Pan

Huang

Wang

, et al. Inhibition of MAPK-mediated ACE expression by compound C66 prevents STZ-induced diabetic nephropathy. J Cell Mol Med 2014; 18(2): 231–241.

270.

Fiordaliso

Leri

Cesselli

, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes 2001; 50(10): 2363–2375.

271.

Uttarwar

Gao

, et al. High glucose up-regulates ADAM17 through HIF-1α in mesangial cells. J Biol Chem 2015; 290(35): 21603–21614.

272.

Restaino

Castorena-Gonzalez

Marshall

, et al. ADAM17 and impaired endothelial insulin signaling in type 2 diabetes. FASEB J 2017; 31(suppl 1): 837-12.

273.

Meza

La Favor

Kim

, et al. Endothelial dysfunction: is there a hyperglycemia-induced imbalance of NOX and NOS? Int J Mol Sci 2019; 20(15): 3775.

274.

Thum

Fraccarollo

Schultheiss

, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 2007; 56(3): 666–674.

275.

Fakhruddin

Alanazi

Jackson

KE.

Diabetes-induced reactive oxygen species: mechanism of their generation and role in renal injury. J Diabetes Res. Epub ahead of print January 2017. DOI: 10.1155/2017/8379327.

276.

Clemmer

Xiang

, et al. Effects of acute and chronic hyperglycemia on lung capillary permeability. FASEB J 2015; 29(suppl 1): 863-22.

277.

Giri

Dey

Das

, et al. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: an update on glucose toxicity. Biomed Pharmacother 2018; 107: 306–328.

278.

Lemkes

Hermanides

DeVries

, et al. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010; 8(8): 1663–1669.

279.

Bus

Chua

Klessens

, et al. Complement activation in patients with diabetic nephropathy. Kidney Int Rep 2018; 3(2): 302–313.

280.

Mauriello

Hair

Rohn

, et al. Hyperglycemia inhibits complement-mediated immunological control of S. aureus in a rat model of peritonitis. J Diabetes Res 2014; 2014: 762051.

281.

Ren

Yang

Wang

, et al. Association of the insulin resistance marker TyG index with the severity and mortality of COVID-19. Cardiovasc Diabetol 2020; 19: 58.

282.

Pandolfi

Barreira

Moreno

, et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax 2017; 72(5): 460–471.

283.

Fontes

Rose

Čiháková

The varying faces of IL-6: from cardiac protection to cardiac failure. Cytokine 2015; 74(1): 62–68.

284.

Hou

Tieu

Ray

, et al. Roles of IL-6-gp130 signaling in vascular inflammation. Curr Cardiol Rev 2008; 4(3): 179–192.

285.

Desai

Leeper

Hynes

, et al. Interleukin-6 causes endothelial barrier dysfunction via the protein kinase C pathway. J Surg Res 2002; 104(2): 118–123.

286.

Rincon

Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012; 33(11): 571–577.

287.

Moore

June

. Cytokine release syndrome in severe COVID-19. Science 2020; 368(6490): 473–474.

288.

Wolf

Waetzig

Chalaris

, et al. Different soluble forms of the interleukin-6 family signal transducer gp130 fine-tune the blockade of interleukin-6 trans-signaling. J Biol Chem 2016; 291(31): 16186–16196.

289.

Rose-John

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8(9): 1237–1247.

290.

Hung

Cherng

Hung

, et al. Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized caveolin-1 in human vascular endothelial cells. J Hypertens 2010; 28(5): 940–951.

291.

Al-Sadi

Boivin

, et al. Interleukin-6 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway activation of claudin-2 gene. PLoS One 2014; 9(3): e85345.

292.

Naruishi

Nishimura

Yamada-Naruishi

, et al. C-Jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect. Transplantation 2003; 76(9): 1380–1382.

293.

Zhou

Xie

, et al. Interleukin-6 regulates iron-related proteins through c-Jun N-terminal kinase activation in BV2 microglial cell lines. PLoS One 2017; 12(7): e0180464.

294.

Shen

TNY

Kanazawa

Kado

, et al. Interleukin-6 stimulates Akt and p38 MAPK phosphorylation and fibroblast migration in non-diabetic but not diabetic mice. PLoS One 2017; 12(5): e0178232.

295.

Zauberman

Zipori

Krupsky

, et al. Stress activated protein kinase p38 is involved in IL-6 induced transcriptional activation of STAT3. Oncogene 1999; 18(26): 3886–3893.

296.

Nandipati

Subramanian

Agrawal

DK.

Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance. Mol Cell Biochem 2017; 426(1–2): 27–45.

297.

Nieto-Vazquez

Fernández-Veledo

De Alvaro

, et al. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 2008; 57(12): 3211–3221.

298.

Birukova

Shah

Tian

, et al. Selective role of vinculin in contractile mechanisms of endothelial permeability. Am J Respir Cell Mol Biol 2016; 55(4): 476–486.

299.

Cohen

Min

Cummings

, et al. Effects of interleukin-6 on the expression of tight junction proteins in isolated cerebral microvessels from yearling and adult sheep. Neuroimmunomodulation 2013; 20(5): 264–273.

300.

Goldman

Sammani

Kempf

, et al. Pleiotropic effects of interleukin-6 in a “two-hit” murine model of acute respiratory distress syndrome. Pulm Circ 2014; 4(2): 280–288.

301.

Klein

Hoke

Fang

, et al. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 2008; 74(7): 901–909.

302.

Mao

Sun

, et al. Hypomethylation of interleukin-6 (IL-6) gene increases the risk of essential hypertension: a matched case-control study. J Hum Hypertens 2017; 31(8): 530–536.

303.

Balakrishnan

Satyamoorthy

Joshi

MB.

Role of IL-6/JAK/STAT pathway in inducing vascular insulin resistance. Mol Cytogenet 2014; 7(1): P96.

304.

Balakrishnan

Satyamoorthy

Joshi

MB.

Inflammation induced insulin resistance is associated with DNA methylation changes in vascular endothelial cells. Can J Biotechnol 2017; 1: 104.

305.

Coomes

Haghbayan

Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol 2020; e2141.

306.

Luo

Liu

Qiu

, et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020; 92(7): 814–818.

307.

Guo

, et al. Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis. bioRxiv 2020.

308.

Zhang

, et al. Cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents 2020; 55(5): 105954.

309.

Michot

Albiges

Chaput

, et al. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Ann Oncol 2020; 31(7): 961–964.

310.

Jankun

COVID-19 pandemic; transmembrane protease serine 2 (TMPRSS2) inhibitors as potential drugs. Transl Univ Toledo J Med Sci 2020; 7: 1–5.

311.

Hoffmann

Schroeder

Kleine-Weber

, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 2020; 64: e00754-20.

312.

The Institute of Medical Science, The University of Tokyo. Identification of an existing Japanese pancreatitis drug, Nafamostat, which is expected to prevent the transmission of new coronavirus infection (COVID-19), https://www.ims.u-tokyo.ac.jp/imsut/en/about/press/page_00002.html (2020, accessed 24 June 2020).

313.

Al-Horani

Desai

UR.

Recent advances on plasmin inhibitors for the treatment of fibrinolysis-related disorders. Med Res Rev 2014; 34(6): 1168–1216.

314.

Caldeira

Alarcão

Vaz-Carneiro

, et al. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ 2012; 345: e4260.

315.

Henry

Zaizafoun

Stock

, et al. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent) 2018; 31(4): 419–423.

316.

Kang

Kao

Lin

, et al. Do outpatient statins and ACEIs/ARBs have synergistic effects in reducing the risk of pneumonia? A population-based case-control study. PLoS One 2018; 13(6): e0199981.

317.

Chen

Zhang

, et al. Losartan attenuates microvascular permeability in mechanical ventilator-induced lung injury in diabetic mice. Mol Biol Rep 2014; 41(2): 809–814.

318.

Fujigaki

Togawa

Miyaji

, et al. Rapid improvement of acute pulmonary edema with angiotensin converting enzyme inhibitor under hemodialysis in a patient with renovascular disease. Ther Apher Dial 2004; 8(2): 148–152.

319.

Leru

Anton

Bocsan

, et al. Acquired angioedema induced by angiotensin-converting enzyme inhibitors-experience of a hospital-based allergy center. Exp Ther Med 2020; 20(1): 68–72.

320.

Meng

Xiao

Zhang

, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9(1): 757–760.

321.

Mancia

Rea

Ludergnani

, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med 2020; 382(25): 2431–2440.

322.

Reynolds

Adhikari

Pulgarin

, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N Engl J Med 2020; 382(25): 2441–2448.

323.

Batlle

Wysocki

Satchell

Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

Clin Sci (Lond) 2020; 134(5): 543–545.

324.

Monteil

Kwon

Prado

, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181(4): 905–913.

325.

Risitano

Mastellos

Huber-Lang

, et al. Complement as a target in COVID-19? Nat Rev Immunol 2020; 20(6): 343–344.

326.

Abe

Sasaki

Ueda

, et al. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: a case report. Medicine (Baltimore) 2017; 96(6): e6056.

327.

Roche

A hypothesized role for dysregulated bradykinin signaling in covid-19 respiratory complications. FASEB J 2020; 34(6): 7265–7269.

328.

Farkas

Kőhalmi

Visy

, et al. Clinical characteristics and safety of plasma-derived C1-inhibitor therapy in children and adolescents with hereditary angioedema—a long-term survey. J Allergy Clin Immunol Pract 2020; 8(7): 2379–2383.

329.

Pharming Group

. Pharming reports encouraging results from use of RUCONEST in COVID-19 patients. Press Release, https://www.pharming.com/nl/node/185#:~:text=Pharming%20Group%20N.V.,the%20University%20Hospital%20Basel%2C%20Switzerland (2020, accessed 24 June 2020).

330.

Tanaka

Ogata

Narazaki

Tocilizumab: an updated review of its use in the treatment of rheumatoid arthritis and its application for other immune-mediated diseases. Clin Med Insights Ther 2013; 5: CMT-S9282.

331.

Mehta

McAuley

Brown

, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395(10229): 1033–1034.

332.

Marfella

Paolisso

Sardu

, et al. Negative impact of hyperglycemia on tocilizumab therapy in COVID-19 patients. Diabetes Metab 2020; 46(5): 403–405.

333.

Magro

SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the’culprit lesion’of ARDS onset? What is there besides tocilizumab? SGP130Fc. Cytokine X 2020; 2(2): 100029.

Angiotensin-converting enzyme 2,the complement system,the kallikrein-kinin system,type-2 diabetes,interleukin-6,and their interactions regarding the complex COVID-19 pathophysiological crossroads

Abstract

Keywords

Introduction

COVID-19

Acute respiratory distress syndrome

Renin angiotensin aldosterone system

Angiotensin-II

Vascular permeability

Angiotensin-converting enzyme 2

Complement system

Kallikrein-kinin system

Type-2 diabetes mellitus

Obesity

Insulin resistance

β-Cell dysfunction

Hyperglycemia

Interleukin 6

Pharmacological interactions

TMPRSS2 inhibition

ACE inhibition/angiotensin II receptor blockage

Complement/kinin inhibition

Interleukin 6 inhibition

Summary

Footnotes

Appendix

Declaration of conflicting interests

Funding

ORCID iDs

References